Maxcyte (MXCT) Operating Leases (2020 - 2026)

Maxcyte (MXCT) has reported Operating Leases for 7 consecutive years, with $15.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Leases fell 8.58% year-over-year to $15.7 million in Q2 2026; TTM through Jun 2026 was $15.7 million, a 8.58% decrease from a year earlier, with the FY2025 full-year figure at $16.5 million, down 3.98% from the prior year.
• Operating Leases was $15.7 million for Q2 2026 at Maxcyte, down from $16.1 million in the prior quarter.
• Over five years, Operating Leases peaked at $18.0 million in Q4 2023 and troughed at $12.8 million in Q1 2022.
• A 5-year average of $16.2 million and a median of $16.3 million in 2025 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases soared 2873.17% in 2022 and fell 8.58% in 2026, its largest moves.
• Over 5 years, Operating Leases stood at $15.9 million in 2022, then increased by 12.74% to $18.0 million in 2023, then dropped by 4.45% to $17.2 million in 2024, then retreated by 3.98% to $16.5 million in 2025, then retreated by 4.63% to $15.7 million in 2026.
• The last three Operating Leases figures came in at $15.7 million (Q2 2026), $16.1 million (Q1 2026), and $16.5 million (Q4 2025), per Business Quant data.